A brain cancer drug beat its historical benchmark by nearly two and a half times, with a p-value most drugs never see, and the stock popped 19% before the open and closed down anyway on 20 times normal volume. A company that had been frozen out of trading for a missed filing came back to the market with a live celebration webcast. Gold drillers in Arizona pushed 150 meters deeper into a system they are still mapping, and a Quebec phosphate junior rang the opening bell at Nasdaq.
Biotech & Life Sciences
NeOnc Technologies’ Brain Cancer Data Beat Its Benchmark, But the Stock Sold Off Anyway
NeOnc Technologies Holdings (Nasdaq: NTHI) reported topline Phase 2a data on August 12 for NEO100, an intranasal treatment for recurrent IDH1-mutant high-grade glioma, a brain cancer with essentially no approved targeted therapy. The trial hit its primary endpoint: 48.9% of patients were progression-free at six months, against a pre-specified historical benchmark of 20%, a result statistically significant at p=0.0047. Median overall survival came in at 26.09 months in a patient population that had already exhausted standard radiation and chemotherapy.
The market’s reaction told a more complicated story than the data alone. NTHI jumped 19% in pre-market trading on the news, then closed the day down 1.73% on trading volume roughly 20.8 times its average. This was a 24-patient, open-label, single-arm study, not a randomized trial, and the release covers topline results only; detailed safety, pharmacokinetic, and subgroup data are still to come. NeOnc’s next step is requesting a Type B meeting with the FDA to discuss a registrational path, a conversation that has not happened yet and carries no guarantee of outcome. The company posted a $14.2 million net loss for the quarter, more than double the prior year.
Tech & Innovation
FOBI AI Returns to Trading After a Cease Trade Order, With a Live Celebration to Mark It
FOBI AI (TSXV: FOBI, Pink: FOBIF) resumed trading on the TSX Venture Exchange on August 13, roughly a month after the exchange revoked a cease trade order tied to a failure to file required disclosure documents. The company marked the return with a live webcast featuring shareholder shoutouts and questions for CEO Rob Anson.
A failure-to-file cease trade order means the company fell behind on its own regulatory paperwork, not that its underlying AI and data intelligence business changed; investors had no ability to buy or sell FOBI shares for the length of the halt regardless of what was happening operationally. Stocks coming off a reinstatement typically see outsized volatility in the first sessions back, in either direction, simply because a month or more of pent-up order flow clears at once. FOBI has not disclosed updated financials alongside the reinstatement itself.
Mining & Minerals
Arizona Gold & Silver Pushes 150 Meters Deeper Into the Perry Zone at Philadelphia
Arizona Gold & Silver (TSXV: AZS, OTCQB: AZASF) reported assays from four diamond drill holes at its Philadelphia project in Arizona, announced August 13. Hole PC26-169 returned 21.79 meters grading 4.1 g/t gold and 5.8 g/t silver within a broader 73.46 meter interval at 1.69 g/t gold, roughly 150 meters vertically above the company’s previously reported high-grade intercepts in the Perry Zone.
A newly expanded Bureau of Land Management permit is what makes the next phase possible: it opens 16 additional drill pads and lets the company test the down-dip continuation of the Perry Zone beneath the Red Hills, deeper drilling that is now underway and expected to run through the rest of 2026. Philadelphia remains a pre-resource exploration project with no NI 43-101 estimate filed, and this week’s results extend the known mineralized envelope rather than define its limits.
Green Energy & Cleantech
First Phosphate Rings the Nasdaq Opening Bell After Its ADR Uplisting
First Phosphate (Nasdaq: PHOS, CSE: PHOS, OTCQX: FRSPF) uplisted its American Depositary Receipts to the Nasdaq Global Market as a Level 2 ADR on August 10, then had its board and management ring the Nasdaq opening bell in New York on August 13 to mark it. The company is building a mine-to-market lithium iron phosphate battery supply chain anchored by its Bégin-Lamarche property in Saguenay, Quebec.
An ADR uplisting is a market-access change, not a financing event: First Phosphate confirmed no new shares were issued and no capital was raised, and its existing CSE, OTCQX, and Frankfurt listings continue unaffected. What it does is put the stock in front of a Nasdaq-only investor base that could not easily hold it before. Whether that translates into higher trading volume or valuation is a separate question the listing itself does not answer.
What to Watch Next
NeOnc plans to request a Type B meeting with the FDA to discuss a registrational path for NEO100. The company also has detailed safety, pharmacokinetic, and subgroup data from the same study still to release.
The company has not disclosed updated financials alongside the reinstatement. The next concrete milestone to watch is whether FOBI catches up on the regulatory filings that triggered the original order in the first place.
Drilling beneath the Perry Zone toward Red Hills is underway and expected to continue through the rest of 2026. Assay results from that deeper phase are the next data point.
No; the company has said explicitly that no new shares were issued and no capital was raised. The next real catalyst to watch is project development progress at Bégin-Lamarche, not the listing itself.
Sources
- NeOnc Technologies posts strong Phase 2a NEO100 data, SEC Form 8-K, StockTitan, August 12, 2026
- NeOnc Reports 48.9% Phase 2a Progression-Free Survival, StockTitan, August 12, 2026
- FOBI AI Inc. Announces Reinstatement to Trading on TSXV Commencing August 13, 2026, GlobeNewswire, August 12, 2026
- Arizona Gold & Silver Intersects 21.79 Metres grading 4.10 g/t Gold at Philadelphia, Junior Mining Network, August 13, 2026
- First Phosphate Announces Uplisting of ADR to Nasdaq Global Market Under Ticker Symbol PHOS, SEC Form 6-K, August 10, 2026
- First Phosphate to Ring Nasdaq Opening Bell, SEC Form 6-K, August 13, 2026
Editorial Disclosure
This week mixes trending stories, already generating notable price or volume reaction, with standard verified small and micro-cap coverage where no comparable trending story existed in a given sector. Tickers discussed in this article: NTHI (NeOnc Technologies Holdings), FOBI / FOBIF (FOBI AI), AZS / AZASF (Arizona Gold & Silver), and PHOS / FRSPF (First Phosphate). aktiego.com has received no compensation from any company, IR firm, or third party in connection with this coverage, and no aktiego.com staff member holds a position in any security named above. Press release dates and primary sources were verified against company IR pages, GlobeNewswire, SEC EDGAR, and Junior Mining Network, and all items fall within the August 9 to 15, 2026 coverage window. All companies named are under $500 million USD in market capitalization as of the dates referenced above, so no size flag applies under this publication’s disclosure tiers. Clinical trial disclosure: NeOnc Technologies’ Phase 2a results come from an open-label, single-arm, 24-patient study without a randomized control group; this is a topline data release, with detailed safety and subgroup analyses still pending, and no FDA meeting on a registrational path has yet occurred. Trading halt disclosure: FOBI AI’s TSXV trading was halted under a cease trade order for failure to file required disclosure documents; reinstated stocks commonly see elevated volatility in their first sessions back independent of any change in the underlying business, and FOBI has not released updated financials alongside its reinstatement. Resource disclosure: Arizona Gold & Silver’s Philadelphia project carries no filed National Instrument 43-101 (NI 43-101) resource estimate; NI 43-101 is the Canadian regulatory standard governing public disclosure of scientific and technical information on mineral projects, and this week’s results extend known mineralization rather than establish a resource. Listing disclosure: First Phosphate’s Nasdaq ADR uplisting involved no new share issuance and no capital raise, per the company’s own disclosure, and does not by itself indicate any change in project economics or development timeline. These are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only, aktiego.com is not a registered investment advisor, and nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
